TTM
−$270.76M
YoY change
-20.8%
5Y CAGR
—
Peak year (2019)
−$12.98M
Cumulative EBITDA
−$990.80M
EBITDA history chart for Erasca (ERAS) from 2019 to 2025
Latest: −$121.44M
EBITDA growth chart for Erasca (ERAS) from 2019 to 2025
Latest: -20.8%
EBITDA history table for Erasca (ERAS) from 2019 to 2025
| 2025 | −$121.44M | -20.8% | +$31.84M | ||
| 2024 | −$153.28M | +26.4% | −$31.97M | ||
| 2023 | −$121.31M | -49.5% | +$118.85M | ||
| 2022 | −$240.16M | +97.0% | −$118.23M | ||
| 2021 | −$121.94M | +229.8% | −$84.97M | ||
| 2020 | −$36.97M | +184.7% | −$23.98M | ||
| 2019 | −$12.98M | — | — |
- 2025−$121.44M-20.8%
- 2024−$153.28M+26.4%
- 2023−$121.31M-49.5%
- 2022−$240.16M+97.0%
- 2021−$121.94M+229.8%
- 2020−$36.97M+184.7%
- 2019−$12.98M—
EBITDA values are taken from Erasca's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Erasca (ERAS)
According to Erasca's latest reported financial statements, the company's current EBITDA (TTM) is −$270.76M. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Erasca (ERAS) reported EBITDA of −$121.44M – declined 20.8% year-over-year.
2019 marks the peak EBITDA at −$12.98M, with the historical low of −$240.16M recorded in 2022.
Erasca EBITDA by Year
Erasca EBITDA 2025: −$121.44M
2025's EBITDA for Erasca came in at −$121.44M, declined 20.8% below 2024.
Erasca EBITDA 2024: −$153.28M
Erasca posted EBITDA of −$153.28M in 2024, grew 26.4% from 2023.
Erasca EBITDA 2023: −$121.31M
In 2023, Erasca reported EBITDA of −$121.31M, plunged 49.5% below 2022.
Erasca EBITDA 2022: −$240.16M
Erasca EBITDA in 2022 was −$240.16M, surged 97.0% from 2021. This figure represents the lowest annual value in the available history.
Erasca EBITDA 2021: −$121.94M
Erasca EBITDA in 2021 was −$121.94M.
See more financial history for Erasca (ERAS).
Sector peers by EBITDA
Healthcare peers of Erasca (ERAS), ranked by their latest EBITDA
| $41.05B | |
| $28.26B | |
| $27.94B | |
| $24.43B | |
| $23.06B | |
| $19.83B | |
| $17.63B | |
| $16.90B |
- $41.05B
- $28.26B
- $27.94B
- $24.43B
- $23.06B
- $19.83B
- $17.63B
- $16.90B
Frequently asked questions
Erasca (ERAS) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation